Simvastatin augmentation for recent-onset psychotic disorder: A study protocol

Discussion We hypothesize simvastatin to lower symptom severity and to prevent or reduce excessive brain tissue loss and cognitive decline, compared to placebo. We expect that simvastatin will be well-tolerated and lead to decreased prevalence of metabolic syndrome. Trial registration ClinicalTrails.gov NCT01999309; EudraCT-number 2013-000834-36.
Source: BBA Clinical - Category: Biochemistry Source Type: research